Garry Merry

Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA.

Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands.

LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands.

ViraTherapeutics GmbH is a biopharmaceutical company that develops virus-based immunotherapeutics for cancer treatment. It specializes in the development of oncolytic cancer vaccines based on Vesicular Stomatitis Virus Glycoprotein G (VSV-GP). The company was founded by Dorothee Holm-von Laer in 2013 and is headquartered in Innsbruck, Austria.

EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively.